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ABSTRACT  
Stimuli-responsive nanocarriers have attracted increasing attention for drug and gene delivery in 
cancer therapy. The present study reports the development of redox-sensitive dendrimersomes 
made of disulphide-linked cholesterol-bearing PEGylated dendrimers, that can be used as drug 
and gene delivery systems. Two disulphide-linked cholesterol-bearing PEGylated generation 3-
diaminobutyric polypropylenimine dendrimers have been successfully synthesized through in 
situ two-step reaction. They were able to spontaneously self-assemble into stable, cationic, 
nanosized vesicles (or dendrimersomes), with lower critical aggregation concentration values for 
high cholesterol-bearing vesicles. These dendrimersomes were able to entrap both hydrophilic 
and hydrophobic dyes, and also showed a redox-responsive sustained release of the entrapped 
guests in presence of a glutathione concentration similar to that of the cytosolic reducing 
environment. The high cholesterol-bearing dendrimersome was found to have a higher melting 
enthalpy, an increased adsorption tendency on mica surface, was able to entrap a larger amount 
of hydrophobic drug and was more resistant to redox-responsive environment in comparison 
with its low cholesterol counterpart. In addition, both dendrimersomes were able to condense 
more than 85% of the DNA at all tested ratios for the low-cholesterol vesicles, and at dendrimer: 
DNA weight ratios of 1:1 and higher for the high-cholesterol vesicles. These vesicles resulted in 
an enhanced cellular uptake of DNA, by up to 15-fold compared with naked DNA with the low-
cholesterol vesicles. As a result, they increased gene transfection on PC-3 prostate cancer cell 
line, with the highest transfection being obtained with low-cholesterol vesicle complex at a 
dendrimer: DNA weight ratio of 5:1 and high-cholesterol vesicle complex at a dendrimer: DNA 
weight ratio of 10:1. These transfection levels were about 5-fold higher than that observed when 
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treated with DNA. These cholesterol-bearing PEGylated dendrimer-based vesicles are therefore 
promising as redox-sensitive drug and gene delivery systems for potential applications in 
combination cancer therapy. 
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INTRODUCTION 
Despite recent advances in the field of cancer gene therapy, the possibility of using therapeutic 
genes combined with anti-cancer drugs for cancer treatment is still hampered by the lack of safe 
delivery systems able to carry both therapeutic DNA and drug simultaneously and to selectively 
deliver them to the tumors, without secondary effects to healthy tissues. 1 The synthesis of novel 
“smart” delivery systems able to overcome these issues is therefore urgently needed. In order to 
remediate this issue, we propose to conjugate cholesterol and PEG to the surface of generation 3-
diaminobutyric polypropylenimine (DAB) dendrimer, with a redox-sensitive disulphide linkage, 
and evaluate the potential use of this novel dendrimer as a drug and gene delivery system.   
Cationic dendrimers are emerging as potential non-viral vectors for delivering nucleic acids 
and anti-cancer drugs to cancer cells. These polymers are highly branched, three-dimensional 
macromolecules with modifiable surface functionalities that have been largely exploited to 
achieve the conjugation of targeting moieties and the binding of drugs or nucleic acids for 
therapeutic applications. Furthermore, their constitutive dendrons delimitate internal cavities, 
that can be used for the encapsulation of various chemically sensitive drugs. Their high aqueous 
solubility, low toxicity, compact globular shape made them ideal carriers for anti-cancer drugs. 2 
Dendrimers can also facilitate the passive targeting of anti-cancer drugs to tumor tissue. This 
selective accumulation of macromolecules in tumors, termed “enhanced permeability and 
retention (EPR) effect”, is the consequence of the combination of reduced lymphatic drainage 
and increased permeability of tumor vasculature to macromolecules. 3 Positively charged 
dendrimers can form stable ionic complexes with negatively charged plasmid DNA, but also 
bind easily to the negatively charged cell surface through electrostatic interactions, leading to 
their cellular internalization by endocytosis. 4-6  
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In this work, we have chosen to use generation 3-diaminobutyric polypropylenimine (DAB) 
dendrimer, as it has been reported to be more efficacious than its higher generations for gene 
transfection. 7 In addition, we recently demonstrated that tumor-targeted generation 3-DAB 
dendrimer complexed to therapeutic plasmid DNA led to successful gene expression and 
therapeutic efficacy in mice bearing subcutaneous tumors following intravenous injection. 8-12  
Recently, the development of various self-assembled nanostructures (such as micelles, vesicles 
or dendrimersomes) based on surface-modified amphiphilic dendrimers following conjugation 
with diverse hydrophobic groups (such as aromatic, long hydrophobic chains, fluorinated 
groups) has shown promises for further biomedical applications. 13-15 Since the hydrophobic 
interactions are one of the main driving forces for any aggregated structure, the conjugation of 
lipidic alkyl chains to dendrimers would not only increase the hydrophobicity of the dendrimers 
and facilitate their self-assembly, but would also make them form more compact and smaller 
sized dendriplexes. 16-17 Based on this, we have chosen to conjugate DAB dendrimer with a more 
lipophilic moiety, cholesterol, which is an essential structural and functional constituent of 
animal cell membrane. Due to its higher hydrophobicity compared with the hydrocarbon chains 
of fatty acids, cholesterol has been previously used for the synthesis of polymer- and surfactant-
based self-assembled nanostructures. 18-20 Cholesterol enhances the stability of the hydrophobic 
rigid microenvironment of nanostructures, helps drug delivery systems to cross the cellular 
membrane more easily, and also increases the transfection efficacy of cholesterol-based gene 
vectors in various cell lines due to its strong fusogenic activity. 21  
Poly(ethylene glycol) (PEG) will also be conjugated to the cholesterol-bearing DAB-
dendrimer as this stealth material was previously reported to increase the water solubility and  to 
reduce non-specific interactions with circulatory proteins, thus leading to an enhanced 
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circulatory life time of drug and gene delivery systems. 22-25 We recently demonstrated that the 
conjugation of low molecular weight PEG (2 kDa) to generation 3- and generation 4-DAB 
dendrimers significantly decreased their cytotoxicity on B16F10-Luc cells, by more than 3.4-fold 
compared to unmodified dendrimers. 26 In addition, these PEGylated dendrimers complexed to 
DNA at dendrimer: DNA ratios of 20:1 and 10:1 were able to increase gene expression on 
B16F10-Luc, A431, DU145, PC3-Luc cells lines, compared to the unmodified dendriplex.   
Stimuli- responsive polymers have gained widespread interest as they are able to undergo 
structural changes in the presence of an external stimulus such as pH, light or redox. In this 
regard, amphiphilic dendrimers containing a disulphide linkage in their structural backbone are 
particularly interesting, as this group can be cleaved into the corresponding thiols in presence of 
a reducing biothiol, such as glutathione (GSH), triggering the destruction of the delivery systems 
and the release of the guest at the desired site of action. 27 This is particularly important in cancer 
therapy, as glutathione is present in abundance in cancer cells: its concentration was found to be 
different in intracellular (~10 mM) and extracellular (<10 µM) compartments of living cells. It is 
nearly 4-fold higher than that of normal tissue in cancer cells. 27  
The objectives of this study were therefore 1) to synthesize and characterize disulphide-linked 
cholesterol-bearing PEGylated amphiphilic DAB dendrimers, 2) to evaluate their self-assembly 
formation into nanostructures and their ability to entrap drugs, 3) to assess the redox sensitivity 
of these nanostructures, 4) to evaluate DNA condensation by the dendrimer-based nanostructures 
and 5) to assess the cell viability, cellular uptake and transfection efficacy of these structures 
complexed with DNA on prostate cancer cells in vitro. 
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MATERIALS AND METHODS 
Materials 
Generation 3- diaminobutyric polypropylenimine dendrimer (DAB) was purchased from SyMO-
Chem (Eindhoven, The Netherlands). Thiocholesterol (CHOLSH), glutathione (GSH), 
trimethylamine (TEA), N-Phenyl-1-naphthylamine (NPN), Nile Red, Rhodamine 6G (R6G), 
trifluoroacetic acid (TFA), the deuterated solvents CDCl3 and D2O, and a double-sided 
Biodialyser (sample reservoir size:  1 mL) were obtained from Sigma Aldrich (Poole, UK). 
Anhydrous tetrahydrofuran (THF), acetonitrile (HPLC grade) and methanol (MeOH) came from 
Fisher Scientific (Loughborough, UK). Orthopyridyl disulfide (OPSS) polyethylene glycol 
(PEG) succinimidyl carboxymethyl ester (OPSS-PEG-SCM) was purchased from JenKem 
Technology (Plano, TX). The expression plasmid encoding β-galactosidase (pCMVsport β-
galactosidase) was obtained from Invitrogen (Paisley, UK). It was purified using an Endotoxin-
free Giga Plasmid Kit (Qiagen, Hilden, Germany). Quanti-iT® PicoGreen® dsDNA reagent and 
tissue culture media were purchased from Life Technologies (Paisley, UK). Vectashield® 
mounting medium containing 4’,6-diamidino-2-phenylindole (DAPI) came from Vector 
Laboratories (Peterborough, UK). Label IT® Fluorescein Nucleic Acid Labeling Kit was 
obtained from Cambridge Biosciences (Cambridge, UK). Passive lysis buffer was obtained from 
Promega (Southampton, UK). Bioware® androgen-irresponsive PC-3M-luc-C6 human prostate 
adenocarcinoma that expresses the firefly luciferase was purchased from Caliper Life Sciences 
(Hopkinton, MA). 
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Synthesis and characterization of the disulphide-linked cholesterol-bearing PEGylated 
dendrimers 
Amine-terminated, generation 3-diaminobutyric poly(propyleneimine) dendrimer (DAB) was 
first conjugated to PEG using OPSS PEG succinimidyl carboxymethyl ester (OPSS-PEG-SCM) 
and then to thiocholesterol (CHOLSH) through disulphide linkage using MeOH-THF (5:1) as 
solvent (Scheme 1). Briefly, TEA (20 equivalents, 66.2 µL) was added as a whole to a solution 
of DAB (1 equivalent, 40 mg) in 1.5 mL MeOH. After 30 minutes of stirring at 20 oC, a freshly 
prepared methanolic solution of OPSS-PEG-SCM (0.5 and 1 equivalents, 27.19 mg and 54.39 
mg respectively for low- and high-cholesterol dendrimers, in 1.5 mL methanol) was added 
dropwise to DAB over 10-12 minutes. The reaction mixture was then stirred at 37 oC for 6 h, 
protected from light.  
Thiocholesterol (0.5 and 1 equivalents (4.77 mg and 9.54 mg) respectively for low-cholesterol 
and high-cholesterol dendrimers, in 0.6 mL THF) was then added as a whole to the reaction 
mixture containing PEGylated DAB. The reaction mixture, initially colorless, gradually became 
yellow, and was left stirring at 37 oC, protected from light. After 15 h, distilled water (5 mL) was 
added to the reaction mixture. The water-soluble modified dendrimers were purified by dialysis 
against distilled water (2 L), changed twice per day for 3 days at 25°C, using dialysis tubing with 
a molecular weight cut-off of 3.5 kDa, to remove organic solvents and excess M-PEG, before 
being filtrated with Whatman cellulose filter paper and freeze-dried using a Christ Epsilon 2-4 
LSC freeze dryer (Osterode am Harz, Germany). The final product DAB-PEG-SS-CHOL 
(DPSC), a white colored compound, was stored at 0-4 oC for long-term storage.  
The infrared spectra of low- and high-cholesterol dendrimers, as well as all the starting materials, 
were obtained using an IRSpirit® QATR-S Fourier Transform infrared (FTIR) spectrophotometer 
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with attenuated total reflectance (ATR) probe (Shimadzu, Kyoto, Japan). Transmittance (4000–
400 cm–1) was recorded at a 4 cm–1 resolution, and spectra were processed with the LabSolutions 
IR® software (Shimadzu, Kyoto, Japan). The 1H-NMR spectra of both low- and high-cholesterol 
dendrimers (2-3 mg in 0.5 mL deuterated solvents) were recorded on a Bruker Avance® III-
HD500 NMR spectrometer (Billerica, MA), using the residual proton resonance of the solvent as 
the internal standard. 
 10 
 
 
Scheme 1. General synthetic scheme of cholesterol-modified PEGylated dendrimers, with m=45.  
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The molecular weights of low- and high-cholesterol dendrimers were determined by Matrix-
assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry, using an 
Axima-CFR® mass spectrometer (Kratos Analytical, Shimadzu, Kyoto, Japan) and α-Cyano-4-
hydroxycinnamic acid as the matrix. The matrix was prepared at a concentration of 10 mg/mL in 
a solvent mixture (acetonitrile/water, 60/40 v/v, with 0.1% TFA). The sample solution (10 µL) 
was added to the matrix solution (10 µL) in 1/1 (v/v) ratio and thoroughly mixed. One µL of this 
mixture was then added to the MALDI sample plate and air-dried before measurement. The 
instrument was operated in a linear mode with a 4 point calibration. A N2 laser operating at 337 
nm was used to generate the ions before being accelerated to 20 kV. 
 
Evaluation of the self-assembly formation of the dendrimers  
The ability for low-and high-cholesterol dendrimers to self-assemble was assessed using a 
steady-state fluorescence technique with N-Phenyl-1-naphthylamine (NPN) as fluorescence 
probe molecule. To this end, 0.75 µL NPN stock solution (1.32 × 10−3 M, 2.89 mg in 10 mL 
methanol) were added to 5-mL plastic vials. Following complete evaporation of the solvent after 
5-6 h, 1 mL low- and high-cholesterol dendrimer solutions prepared at concentrations ranging 
from 1 to 400 µg/mL in PBS (pH 7.4), was added to the vials, making the final probe 
concentration 1 × 10−6 M. Each sample was vigorously vortexed for 5 minutes and then 
incubated for 16 h at 20 oC, protected from light, before measurement. Fluorescence spectra of 
NPN were then recorded with a Varian Cary Eclipse Fluorescence spectrophotometer (Palo Alto, 
CA) (λexc: 340 nm, λem: 360-600 nm, excitation and emission slit at 5 nm and 10 nm 
respectively). 
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Hydrodynamic size and zeta potential of dendrimer self-assembled nanostructures  
The hydrodynamic diameter (dH) and zeta potential of dendrimer self-assembled nanostructures 
in aqueous medium (PBS, pH 7.4) at 37 oC were measured at concentrations ranging from 50 to 
400 µg/mL (over CAC value) by dynamic light scattering (DLS) using a Malvern Nano ZS 
instrument (Malvern Instruments, Malvern, UK). A 4 mW He-Ne laser (λ = 632.8 nm) was used 
as a source and scattering photons were collected at 173o scattering angle. 
 
Formation of low-and high-cholesterol dendrimer-based vesicles  
Observation of the morphology of the self-assembled nanostructures 
 The morphology of the low-cholesterol and high-cholesterol dendrimer-based nanostructures 
(400 µg/mL in PBS pH 7.4) was observed by transmission electron microscopy, using a JEOL 
JEM-1200EX transmission electron microscope (Jeol, Tokyo, Japan) operating at an accelerating 
voltage of 80 kV. Three µL of each sample in PBS (pH 7.4) was drop cast on a carbon-coated 
copper grid (400 mesh size) and was kept in desiccators overnight for drying before imaging.  
 
Encapsulation of hydrophilic dye R6G by the self-assembled nanostructures  
R6G solution (1.02 x 10−2 M, 4.89 mg/mL in methanol, 28.18 µL and 19.85 µL) was respectively 
added to 1.15 mg of low-cholesterol and 0.81 mg of high-cholesterol dendrimers. Following 
evaporation of methanol by a stream of N2 gas, the mixture of dendrimers with R6G was soaked 
in 1 mL PBS buffer pH 7.4 for 3 h (until the dispersion became homogeneous) and vortexed for 
10 min. PBS buffer (pH 7.4) was then added to obtain a final dendrimer solution with a 
concentration of 400 µg dendrimer per mL and 47 µg R6G per mL (1x10−4 M). The dendrimer 
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solution containing R6G was vortexed for 2 min and incubated for 20 h at 25 oC to allow 
encapsulation of the hydrophilic dye. To remove the unencapsulated dye, the dendrimer solution 
(1 mL) was dialyzed in a double-sided Biodialyzer cell using a dialysis membrane with a 
molecular weight cut-off of 2000 Da, against 60 mL PBS buffer (pH 7.4) for 24 h with 4 changes 
of the buffer. The dialyzed solution was kept protected from light and its fluorescence was 
quantified by spectrofluorimetry (λex: 480 nm, λem: 500-700 nm), using a Varian Cary Eclipse 
spectrofluorometer (Agilent Technologies, Santa Clara, CA).  
 
Thermal analysis of phase transition behavior of low-and high-cholesterol dendrimer-based 
vesicles 
Transmittance of low-cholesterol and high-cholesterol dendrimer-based vesicles (400 µg/mL in 
PBS buffer pH 7.4) was measured at temperatures ranging from 20 oC to 90 oC, using a Varian 
Model-Cary 5000 spectrophotometer (Agilent Technologies, Santa Clara, CA), with a Cary 
automated temperature controller UV0904M400 (Agilent Technologies, Santa Clara, CA), to 
measure the cloud point. Differential scanning calorimetry (DSC) measurements for low-
cholesterol and high-cholesterol dendrimer-based vesicles (2 mg/mL in PBS pH 7.4) were done 
using a Netzsch DSC214 Polyma differential scanning calorimeter (Netzsch-Gerätebau GmbH, 
Selb, Germany) to measure the phase transition behavior of the vesicles. To this end, 3.1 ± 0.1 
mg of sample was transferred to a 40 μL aluminium pan by micropipetting. Pans were 
hermetically sealed with aluminium lids. Blank and reference pans were prepared with 3.1 ± 0.1 
mg of PBS solution. Samples were cooled to -15°C at a rate of 2 °C/min and held for 5 min at -
15°C prior to heating at a rate of 2 °C/min. A repeat cycle was carried out on each sample. Blank 
correction was carried out with the PBS solution under the same measurement conditions prior to 
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sample analysis. Analysis of the results was carried out with Netzsch Proteus Analysis Software 
v7.0.1 (Netzsch-Gerätebau GmbH, Selb, Germany), with onset temperature, peak temperature 
and enthalpy of measured peaks determined.  
 
Atomic force microscopy (AFM) imaging of dendrimer-based vesicles  
Low-cholesterol and high-cholesterol dendrimer-based vesicles were visualized by atomic force 
microscopy (AFM) to assess their size and shape. Data were collected by a Dimension Icon® 
AFM (Bruker, Santa Barbara, CA) using a PeakForce Tapping® scanning mode at 20 oC with a 
ScanAsyst-Air® probe (Bruker, Santa Barbara, CA) with nominal spring constant k =0.4 N/m 
and nominal tip radius of 2 nm. One drop (10 µL) of dendrimer solution (400 µg/mL in PBS pH 
7.4) was placed on a freshly cleaved mica surface and was left to dry at 20 oC overnight, 
protected from light, before measurements. All images were analyzed using NanoScope Analysis 
1.5 software (Bruker, Santa Barbara, CA). Height images were corrected by first order flattening. 
 
Evaluation of redox sensitivity of the dendrimer-based vesicles  
Size measurement  
The hydrodynamic diameter was measured at different time intervals by dynamic light scattering 
as described above for low- and high-cholesterol dendrimer-based vesicles (1.5 mL, 100 µg/mL 
in PBS pH 7.4), incubated with or without glutathione (10 µm and 10 mM) at 37 oC. Sample 
solutions in presence and absence of glutathione were prepared by mixing 75 μL of stock 
dendrimer solutions (2 mg/mL) with 150 μL glutathione solution (100 mM or 100 μM) and 1275 
μL PBS (pH 7.4), or 1425 μL PBS solution (pH 7.4) for control measurement. The samples were 
then incubated in the dark under stirring at 37 oC for 48 h.  
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Redox-sensitive release of Nile Red from the vesicles 
The redox-triggered release of an entrapped lipophilic dye, Nile Red, from the low- and high-
cholesterol dendrimer-based vesicles was assessed using the reducing agent glutathione.  
In order to entrap Nile Red into the vesicles, low- and high-cholesterol dendrimer-based 
vesicles (2 mg/mL) were prepared in PBS (pH 7.4) and equilibrated for 24h at 20 oC. Nile Red 
solution (40 μL, 5 mg/mL in methanol) was added into an empty plastic vial and the methanol 
was evaporated by a stream of N2 gas. Then, 1 mL of stock dendrimer-based vesicles was added 
to the vial containing Nile Red and the mixed dispersion was stirred at 20 oC for 40 h, protected 
from light. The dispersions were then filtered through hydrophilic cellulose acetate membranes 
with pore size of 0.45 μm to remove free Nile Red.  
To test the glutathione-sensitive release of entrapped Nile Red from the vesicles, 75 μL of Nile 
Red-entrapped vesicles (2 mg/mL) were mixed with either 1425 μL PBS for control 
measurement, or 150 μL glutathione solutions (100 mM or 100 μM) and 1275 μL PBS to get the 
experimental concentration in absence and presence of glutathione. Fluorescence spectra of Nile 
Red were recorded (λex: 540 nm, λem: 560-800 nm, excitation and emission slits at 10 nm and 20 
nm respectively) at different time intervals, considering the addition of glutathione solution as 
the start of the experiment.  
 
Characterization of dendriplex formation  
Evaluation of DNA condensation  
The ability of cholesterol-bearing dendrimers to complex negatively charged plasmid DNA 
encoding β-galactosidase was evaluated by a PicoGreen® assay, performed according to the 
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supplier's protocol. On the day of the experiment, PicoGreen® reagent was diluted 200-fold in 
Tris–EDTA (TE) buffer (10 mM Tris, 1 mM EDTA, pH 7.5).  DNA solution (500 μL, 10 μg/mL 
in TE buffer) was added to each sample of dendrimer solution (500 μL in TE buffer) and 
vortexed to prepare 1 mL of dendrimer: DNA complexes, with dendrimer: DNA weight ratios of 
20:1, 10:1, 5:1, 2:1, 1:1, 0.5:1 and 0:1. One mL PicoGreen® solution was then added to the 
dendriplexes and vortexed immediately before the first measurement. The fluorescence intensity 
of PicoGreen® (λex: 480 nm, λem: 520 nm, excitation and emission slits: 5 nm each) in presence 
of the dendriplexes was measured at various times using a Varian Cary Eclipse Fluorescence 
spectrophotometer (Palo Alto, CA). Results were represented as percentage of DNA 
condensation. 
Agarose gel retardation assay was also performed to assess DNA condensation ability of the 
dendrimers. Dendriplexes were prepared at various dendrimer: DNA weight ratios from 20:1 to 
0.5:1, with a constant DNA concentration of 20 µg/mL. After mixing with the loading buffer (2 
µL), the samples (10 µL) were loaded on a 1X Tris-Borate-EDTA (TBE) (89 mM Tris base, 89 
mM boric acid, 2 mM Na2-EDTA, pH 8.3) buffered 0.8% (w/v) agarose gel containing ethidium 
bromide (0.4 µg/mL), with 1x TBE as a running buffer and HyperLadder 1Kb as a DNA size 
marker.  The gel was run at 50 V for 1 h and then photographed under UV light. 
 
Size and zeta potential measurement  
Hydrodynamic diameter and zeta potential of dendriplexes was measured by dynamic light 
scattering (DLS) using a Malvern Nano ZS instrument (Malvern Instruments, Malvern, UK), 
immediately after mixing a fixed amount of DNA (50 µg) to various dendrimer concentrations in 
5% glucose solution (dendrimer: DNA weight ratios: 0.5:1, 1:1, 2:1, 5:1, 10:1 and 20:1).  
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Observation of the morphology of the dendriplexes 
The morphology of the dendriplexes was observed using TEM as described above at an 
accelerating voltage of 80 kV. Three µL of each dendriplex solution in PBS (pH 7.4) was drop 
cast on a carbon-coated copper grid (400 mesh size) instantaneously after mixing of a fixed 
amount of DNA (50 µg) to various dendrimer concentrations (dendrimer: DNA weight ratios: 
5:1 and 10:1). The grid was then kept in a desiccator overnight for drying before imaging. 
 
In vitro analysis  
Cell culture  
Human prostate adenocarcinoma PC3M-Luc cells were grown as monolayers in Minimum 
Essential Medium (MEM), supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) L-
glutamine and 0.5% (v/v) penicillin–streptomycin. Cells were cultured at 37 °C in a 5% carbon 
dioxide, humid atmosphere. 
 
Evaluation of cell viability 
The cell viability of modified dendrimers was evaluated using a standard MTT assay. To this 
end, PC-3 cells were seeded at a density of 5 000 cells per well in 96-well plates and grown at 37 
°C for 24 h in a 5% carbon dioxide, humid atmosphere. They were then treated with different 
concentrations of dendrimer solution (ranging from 5 to 45 µg/mL) for various incubation time 
(24, 48 and 72 h). Following treatment, 50 µL of MTT solution (5 mg/mL in PBS pH 7.4) was 
added in each well and incubated for 4 h at 37 °C. Medium was then removed and 200 µL 
DMSO was added in each well to solubilize the formazan dye produced during the reduction of 
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MTT by the living cells. The amount of formazan dye was measured using spectrophotometry at 
540 nm with a Multiskan Ascent® plate reader (Thermo Scientific, Waltham, MA).  
 
Cellular uptake of dendriplexes  
Qualitative analysis  
The cellular uptake of low-and high-cholesterol, dendrimer-based vesicles complexed to DNA 
was qualitatively assessed using confocal microscopy. Labeling of plasmid DNA with the 
fluorescent probe fluorescein was performed using a Label IT® Fluorescein Nucleic Acid 
Labeling kit, as described by the manufacturer. PC-3 cells were seeded on coverslips in 6-well 
plates at a concentration of 105 cells per well and grown for 48 h at 37 °C. The cells were then 
treated with fluorescein-labelled DNA (2.5 µg/well) complexed to low-and high-cholesterol 
vesicles, at a dendrimer: DNA weight ratios of 5:1 and 10:1 for 2 hours at 37 °C. Control wells 
were also prepared with naked DNA or remained untreated. The cells were then washed three 
times with 3 mL phosphate buffered saline (PBS) before being fixed with 2 mL methanol for 10 
min at 20 oC. They were then washed again with 3 mL PBS. Upon staining of the nuclei with 
Vectashield® mounting medium containing DAPI, the cells were examined using a Leica TCS 
SP5 confocal microscope (Wetzlar, Germany).  DAPI (which stained the cell nuclei) was excited 
with the 405 nm laser line (emission bandwidth: 415-491 nm), fluorescein (which labelled the 
DNA) was excited with the 514 nm laser line (emission bandwidth: 550-620 nm). 
 
Quantitative analysis  
Quantification of cellular uptake of the dendrimer-based vesicles complexed to DNA was carried 
out by flow cytometry. PC-3 cells were seeded at a density of 105 cells per well in 6-well plates 
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and grown at 37 °C for 72 h, before being treated fluorescein-labeled DNA (2.5 µg DNA/well) 
complexed with the vesicles at dendrimer: DNA weight ratios of 5:1 and 10:1. Other wells were 
treated with DAB dendriplex and DNA solution as positive and negative controls respectively. 
After 2 h incubation with the treatments, single cell suspensions were prepared (using 250 µL 
trypsin per well, followed by 500 µL medium per well once the cells have detached), before 
being analyzed using a FACSCanto® flow cytometer (BD, Franklin Lakes, NJ). Their mean 
fluorescence intensity was analyzed with FACSDiva® software (BD, Franklin Lakes, NJ), 
counting ten thousand cells (gated events) for each sample.  
 
Evaluation of gene expression of the DNA complexed with the dendrimer-based vesicles 
The transfection efficacy of the DNA complexed by the dendrimer-based vesicles was assessed 
using a plasmid DNA encoding β-galactosidase (pCMV β-gal). PC-3 cells were seeded at a 
concentration of 2 000 cells/well in 96-well plates and left to grow for 72 h at 37 °C in a 5% CO2 
atmosphere. They were then treated with the complex in quintuplicate at various dendrimer: 
DNA weight ratios (20:1, 10:1, 5:1, 2:1, 1:1 and 0.5:1). Naked DNA was used as a negative 
control and DAB-DNA (dendrimer: DNA weight ratio 5:1) served as a positive control. DNA 
concentration (1 µg/mL) was kept constant throughout the experiment. After treatment, the cells 
were incubated for 24 h, 48 h and 72 h before analysis. They were then lysed with 1X passive 
lysis buffer (PLB) (50 µL/well) for 20 min at 37 oC and then tested for β-galactosidase 
expression. Briefly, 50 µL of the assay buffer (2 mM magnesium chloride, 100 mM 
mercaptoethanol, 1.33 mg/mL O-nitrophenyl- β-D-galactosidase, 200 mM sodium phosphate 
buffer, pH 7.3) was added to the cell lysates and incubated for 2 h at 37 oC. The absorbance of 
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the samples was subsequently read at 405 nm using a Multiskan Ascent® plate reader (MTX Lab 
Systems, Brandenton, FL). 
 
Statistical analysis 
Results were expressed as means ± standard error of the mean. Statistical significance was 
assessed by one-way analysis of variance and Tukey multiple comparison post-test (Minitab® 
software, State College, PE). Differences were considered statistically significant for P values 
lower than 0.05. 
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RESULTS AND DISCUSSION 
Synthesis and characterization of the disulphide-linked cholesterol-bearing PEGylated 
dendrimers 
The synthesis of low- and high-cholesterol disulphide-linked PEGylated dendrimers was 
confirmed by FTIR, 1H-NMR and MALDI-TOF MS. Infrared (ATR) spectra of low-and high-
cholesterol dendrimers (Figure S1) showed the presence of a new peak at 1645-1646 cm-1 
(corresponding to an amide bond) and the absence of a peak at 1719-1740 cm-1 (corresponding to 
the succinimidyl carboxymethyl ester group), in comparison with that of the starting materials 
OPSS-PEG-SCM DAB-G3 and CHOLSH (Figure S2), thus demonstrating the conjugation of 
PEG to DAB through amide bond formation.  
The conjugation of cholesterol and PEG to DAB was also confirmed by 1H-NMR, as follows: 
1H-NMR (CDCl3): δ2.39-2.43 ppm, DAB (N-CH2-CH2-CH2-N) (a); δ2.44-2.46 ppm, DAB (N-
CH2-CH2-CH2-NH2) (b); δ3.98 ppm, PEG (NH-CO-CH2-OCH2CH2) (c); δ5.35-5.36 ppm, 
cholesterol (C=CH-CH2) (d); δ0.67 ppm, cholesterol (CH2CCH3-CH-CH2CH2CCH3) (e) (Figure 
S3).  
Molecular weights of both low- and high-cholesterol dendrimers were assigned using MALDI-
TOF mass spectrometry (Figure S4). Both mass spectra mainly exhibited singly charged 
molecular ions [M]+ with their fragmented products. The average molecular weight of low-
cholesterol PEGylated DAB was 4210 Da, indicating that the ratios of conjugated PEG as well as 
cholesterol per dendrimer were nearly 1. The average molecular weight of its high-cholesterol 
counterpart was 6492 Da, demonstrating that these ratios were nearly 2 (Figure S4). MALDI-
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TOF mass spectrometry data was analyzed to calculate the percentage of conjugated lipid to 
dendrimer, which were 9.5% for the low-cholesterol dendrimer and 12.5% for the high-
cholesterol dendrimer.  
Both low-and high-cholesterol dendrimers showed relatively low % yield (respectively 43% and 
33% for low- and high-cholesterol dendrimers). 
 
 1H NMR spectrum of high-cholesterol dendrimer in D2O showed the peaks of DAB and 
PEG, but no peak for cholesterol (Figure S5), unlike the NMR spectrum of high-cholesterol 
dendrimer in CDCl3, where peaks for cholesterol were visible (Figure S3B). The absence of the 
NMR peaks for cholesterol in D2O and the reappearance of these peaks in CDCl3 demonstrated 
the amphiphilic nature of the modified dendrimer with a possible self-organization tendency to 
form self-assembled nano- or microstructure in aqueous medium. 28 The two-step in situ 
synthetic procedure applied in this study allowed the successful conjugation of PEG and 
cholesterol on one amine group, which helped to retain more primary amine groups on the 
surface of the dendrimers and is crucial for the complexation of nucleic acids.  
  
Evaluation of the self-assembly formation of the dendrimers 
To study the possible self-assembly of the low-and high-cholesterol PEGylated amphiphilic 
dendrimers, steady-state fluorescence technique using NPN as probe molecule was used. Being a 
hydrophobic fluorescent probe, NPN is weakly fluorescent in water, but its fluorescence intensity 
increases when it is being solubilized in a non-polar medium or within the hydrophobic core of 
any self-assembled aggregates. 29 The fluorescence intensity of NPN exhibited a gradual rise of 
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fluorescence with increasing concentrations of dendrimer in PBS (pH 7.4) with a complete blue 
shift of the λmax (from ~465 nm at a dendrimer concentration of 0 µg/mL to ~420 nm at a 
dendrimer concentration of 400 µg/mL) (Figure S6), demonstrating the solubilization of the 
probe in the hydrophobic domain of the self-assembled aggregate formed by these amphiphilic 
dendrimers. The initial plateau of the curve showed concentration-independent fluorescence 
intensity for dendrimer concentrations below 10 µg/mL, which reveals that self-association of 
the dendrimers starts through the inter-chain aggregation above the critical aggregate 
concentration, without formation of unimer aggregates (Figure 1). The critical aggregation 
concentration (CAC) values were calculated from the inflection point of the plot of relative 
fluorescence intensities (I/Io, where I and Io are respectively the fluorescence intensities in the 
presence and absence of dendrimer) of NPN at various dendrimer concentrations (Figure 1). The 
CAC values decreased by increasing the degree of cholesterol conjugation: the high-cholesterol 
dendrimer had a comparatively lower CAC value (~10 µg/mL) than that of the low-cholesterol 
dendrimer (~21 µg/mL). This might be attributed to the overall higher hydrophobe content of the 
high-cholesterol dendrimer in comparison with the low-cholesterol dendrimer, as the self-
assembled aggregate formation occurs mainly through the hydrophobic interaction among the 
lipid molecules. The CAC values for the low and high cholesterol-modified PEGylated 
dendrimers were found to be close to that obtained with generation 1-, generation 2- and 
generation 3-PAMAM dendrimer conjugated to cholesterol at 40% mole ratio of 
cholesterol/primary amine (12.5 ± 3.2 µg/mL for generation 2-PAMAM-cholesterol, 28.9 ± 4.1 
µg/mL for generation 1-PAMAM-cholesterol and 28.7 ± 3.5 µg/mL for generation 3-PAMAM-
cholesterol). 30 They were lower than the CMC observed when using generation-3 PAMAM 
dendrimers conjugated to cholesterol at 6% and 15% mole ratio of cholesterol/primary amine 
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(respectively 86.6 ± 5.6 µg/mL and 50.2 ± 5.1 µg/mL). 31 These low CMC facilitated the 
incorporation of the PAMAM-cholesterol in the PEG-stabilized liposome bilayer. In addition, 
the CAC values for the low- and high-cholesterol dendrimers were found to be well below those 
of dendrimersomes and glycodendrimersomes prepared from self-assembling amphiphilic Janus 
dendrimers (typically between 0.5 mg/mL and 1 mg/mL). 32 The CAC values obtained in our 
experiments were low, indicating the stability of the self-assemblies in dilute conditions, which 
is a very important parameter for future applications as drug and gene delivery systems. 
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Figure 1. Relative fluorescence intensity (I/Io) of N-Phenyl-1-naphthylamine in function of the 
concentration of low-cholesterol dendrimer (A, R2: 0.99) and high-cholesterol dendrimer (B, R2: 
0.96) in PBS buffer (pH 7.4) 
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Hydrodynamic size and zeta potential of dendrimer self-assembled nanostructures 
Both low-cholesterol and high-cholesterol dendrimer-based self-assembled nanostructures 
displayed an average size less than 230 nm at all the concentrations tested, with low 
polydispersity index (PDI) values (respectively 0.25-0.4 and 0.2-0.25 for low and high 
cholesterol dendrimer-based nanostructures) (Figure 2).  Their size gradually decreased from low 
to high concentrations, to reach their smallest sizes of 91.3 nm ± 11.3 nm and 133.4 nm ± 48.8 
nm respectively for low-cholesterol and high-cholesterol dendrimer-based nanostructures. This 
decrease might be due to the formation of more compact and stable nanostructures at high 
concentrations, resulting from increased hydrophobic interactions among cholesterol at higher 
dendrimer concentrations. These sizes were generally lower than those reported for spontaneous 
or stimuli-sensitive, dendrimer-based vesicular structures made of C17 and C18 alkyl chain-
bearing polyamine amphiphilic dendrimers, that ranged from 200 to 500 nm. 33-34 Furthermore, 
they were below the cut-off size for extravasation, which is 400 nm for most tumors. 35   
Zeta potential experiments demonstrated that these self-assembled nanostructures were bearing 
a positive zeta potential comprised between 4 mV and 7 mV for both dendrimers. Zeta potential 
increased with increasing concentrations, to reach maximum values of 5.7 mV ± 0.5 mV and 6.5 
mV ± 0.3 mV respectively for low-cholesterol and high-cholesterol dendrimer-based 
nanostructures. It was similar as that obtained with disulphide cross-linked hyperbranched 
PAMAM-based vesicles (~5 mV). 36 These positively charged formulations would increase their 
electrostatic interactions with the negatively charged cellular membranes, resulting in an 
enhanced cellular uptake of the nanostructures through internalization mechanisms. 37 The 
modulation of the amount of cholesterol within the dendrimers did not impact on the size and 
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zeta potential of the low-cholesterol and high-cholesterol dendrimer-based self-assembled 
nanostructures, that were no statistically different at all measured concentrations.  
 
Figure 2. Size (A) and zeta potential (B) of low-cholesterol (■) and high-cholesterol (○) 
dendrimers self-assembled nanostructures in PBS buffer (pH 7.4) at 37 oC  
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Formation of low-and high-cholesterol dendrimer-based vesicles 
Observation of the morphology of the self-assembled nanostructures 
TEM images of the low-and high-cholesterol dendrimer-based nanostructures revealed the 
presence of spherical unilamellar vesicles. Their size (lower than 50 nm) was smaller than that 
observed with DLS, as TEM images were taken following drying of the samples, unlike DLS, 
where hydrodynamic sizes were being measured.  
 
Encapsulation of hydrophilic dye R6G by the self-assembled nanostructures 
Normalized fluorescence spectra of the cationic hydrophilic dye R6G showed the quenching of 
the fluorescence intensity of the dye in presence of the dendrimer-based vesicles, compared with 
that of absorbance-matched dye solution (Figure 3). As R6G dye exhibits self-quenching 
properties, it is possible to investigate whether it is sequestered inside a vesicle-type 
nanostructure. When a certain amount of hydrophilic dye, R6G is uniformly distributed in water, 
it fluoresces without any self-quenching effect. However, when some of the dye is being 
encapsulated within the aqueous core of the dendrimer-based vesicles, the local concentration of 
the dye within this small-volume core increases, leading to self-quenching. 38 These results 
therefore demonstrated the encapsulation of R6G in the aqueous core of the dendrimer-based 
vesicles, with drug loading efficiencies of 0.28 % and 0.20 % respectively for the low-and high-
cholesterol dendrimer-based vesicles. This further confirms that the structure of the self-
assembly nanostructure is a vesicle, and not a micelle, as a micelle would not be able to entrap 
hydrophilic dyes.  
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Figure 3. Demonstration of the formation of low- and high-cholesterol dendrimer-based 
vesicles:  
- Unstained TEM images of low-cholesterol (A) and high-cholesterol (C) dendrimer-based 
vesicles (400 µg/mL in PBS, pH 7.4) 
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- Normalized fluorescence spectra of R6G in the presence and absence of low-cholesterol (B) 
and high-cholesterol (D) dendrimer-based vesicles (400 µg/mL in PBS, pH 7.4)  
 
Thermal analysis of phase transition behavior of low-and high-cholesterol dendrimer-based 
vesicles 
Thermal stability at physiological conditions (pH 7.4, 37 oC) is an important parameter for drug 
delivery carriers. Percent transmittance (%T) with increasing temperature (Figure S7) showed 
more than 95% transmittance for both low-cholesterol and high-cholesterol dendrimer-based 
vesicles (400 µg/mL in PBS buffer pH 7.4), suggesting there was no lower critical solution 
temperature (LCST) or cloud point (CT) in temperature ranging from 20 to 90 ○C. These results 
demonstrated that there should be no phase separation of dendrimer-based vesicles at body 
temperature (37 oC) and therefore no premature release of any entrapped pharmaceutically active 
agent at body temperature. The cationic nature and PEGylation of both cholesterol-modified 
amphiphilic dendrimers make them more hydrophilic and stable in water at even higher 
temperatures at this concentration in comparison with cholesterol-based PEGylated polymers 
(LCST~57-65 oC) or high molecular-weight PEGylated biaryl-based amphiphilic dendrons 
(LCST~31-42 oC). 18,39  
 To investigate the impact of the steroidal lipid molecule on the backbone structure of the 
PEGylated dendrimers, differential scanning calorimetry was performed. An endothermic 
melting peak (Tm) was visible at nearly 0 °C (-0.6 °C and -0.8 °C respectively for low-
cholesterol and high-cholesterol dendrimer-based vesicles) during the heating phase.  It also 
appeared during the second heating cycle (Figure 4). This melting peak (Tm) of heating is 
responsible for the phase change of the vesicle membrane, from “gel” state to “liquid crystalline” 
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or “fluid” state, which is similar to that of another unsaturated lipid-based liposomal formulation, 
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC; Tm= ‒2 oC). 40-41 The presence of 
unsaturation in cholesterol and/or in the disulphide bond might be the reason for such low Tm. 
Although both dendrimer-based vesicles showed nearly the same melting peak, the melting 
enthalpy (area under the endothermic melting curve) decreased to a lower value from high-
cholesterol to low-cholesterol vesicles (Table S1), due to a progressive ‘‘dilution’’ of the lipids 
(cholesterol) in the membrane from high-cholesterol to low-cholesterol dendrimer-based 
vesicles. 41  
 
 
 
Figure 4. DSC spectra of low-cholesterol (DSPCL, red) and high-cholesterol (DSPCH, blue) 
dendrimers for the first heating (2 °C.min−1) and second heating cycles (2 °C.min−1) 
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AFM imaging of vesicular aggregates 
AFM images were recorded for both dendrimer-based vesicles in PBS (pH 7.4) adsorbed after air 
drying on freshly cleaved mica surface. Low-cholesterol, dendrimer-based vesicles kept their 
vesicular structure, but their shape was slightly deformed and changed from spheres to spherical 
caps, as seen in the cross-section analysis (Figure 5). This was probably due to the strong 
adsorption of lipid-bearing dendrimer onto the freshly cleaved mica surface, which was also the 
reason behind the broadening of their diameter. The effect of adsorption of the vesicles onto 
mica surface was even enhanced in the case of high-cholesterol dendrimer-based vesicles, whose 
dendrimers contain a larger amount of lipids. This led to a more pronounced deformation of the 
high-cholesterol vesicles and a wider spreading of these vesicles on the mica surface (Figure 5). 
42-43 By comparison, the preparation of TEM carbon grids resulted in a much limited deformation 
of the vesicles, due to the lower surface energy of these grids, whereas the vesicles were 
subjected to pronounced deformation when in contact with the mica surface, even leading to 
fusion, as reported for some liposomes and polymersomes. 42-43 The spherical caps had an 
average typical height of about 20 nm and 10 nm respectively for low-cholesterol and high-
cholesterol dendrimer-based vesicles, which further corroborates the spreading of the high-
cholesterol vesicles, producing an almost flat film on the mica surface because of their higher 
lipid content. 42-43 
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Figure 5 Tapping mode AFM phase and height contrast images of 5 x 5 μm surfaces of low-
cholesterol (A, B) and high-cholesterol (D, E) dendrimer-based vesicular solution (400 µg/mL) 
adsorbed on a mica (silicon) surface. The average heights were measured by cross section 
analysis for low-cholesterol (C) and high-cholesterol (F) vesicles, revealing the shape of a 
spherical cap. 
 
Evaluation of redox sensitivity of the dendrimer-based vesicles 
Size measurement 
The bilayer of the dendrimer-based vesicles is composed of hydrophobic cholesterol, which is 
conjugated to the PEGylated dendrimer via a disulfide linkage sensitive to the reducing agent 
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glutathione (Scheme 2). The redox-responsiveness of these vesicles was investigated by 
monitoring the changes in the hydrodynamic sizes of the vesicles via dynamic light scattering 
measurements in presence or absence of glutathione at different time intervals and at different 
glutathione concentrations (10 µM and 10 mM, corresponding to reducing environments in the 
extracellular and intracellular compartments respectively).  
 
 
 
 
Scheme 2. Schematic representation of the formation of vesicles by both low-cholesterol and 
high-cholesterol DAB-PEG-S-S-CHOL dendrimers, showing encapsulation of hydrophilic and 
hydrophobic drugs respectively in the aqueous core and hydrophobic bilayer. 
 
Low-cholesterol vesicles displayed similar sizes (less than 200 nm) in presence of 10 µM or 
without glutathione at all the tested durations. However, a higher concentration (10 mM) of 
glutathione induced a pronounced increase in size from 9 h (104.3 ± 15.2 nm) to 48 h (716.3 ± 
16.1 nm), therefore demonstrating that the vesicles have disintegrated at that time (Figure 6A).  
A similar trend was also observed for the high-cholesterol vesicles in presence of 10 mM 
glutathione from 9 h (155.1 ± 66.1 nm) to 48 h (771.1 ± 28.2 nm) although the vesicle size at 24 
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h (240.3 ± 78.3 nm) was lower than that observed with low-cholesterol vesicles (331.3 ± 37.2 
nm) (Figure 6B). This increase in size can be attributed to the cleavage of the disulfide bonds and 
disintegration of the vesicles, forming larger, unstable and less compact aggregates. The high-
cholesterol PEGylated dendrimer, having a larger amount of cholesterol and larger number of 
disulfide linkages than its low-cholesterol counterpart, may allow a more limited access for the 
hydrophilic glutathione to its lipidic bilayer (thus explaining the size differences at 24 h) and 
may require a larger amount of glutathione to break the excess disulphide bonds than low-
cholesterol dendrimer. Both low-and high-cholesterol vesicles expressed strong redox sensitivity 
in presence of 10 mM glutathione, corresponding to reducing environment in the intracellular 
compartment. These effects were similar to those observed for redox-responsive PEGylated 
generation 4-PAMAM dendrimers (that show a significant decrease of particle size from 16.9 ± 
0.8 nm to 12.5 ± 0.5 nm occurring in presence of 10 mM glutathione)41 and disulphide cross-
linked hyperbranched PAMAM dendrimer-based vesicles, whose size changed from 110 nm to 
23 nm in presence of 10 mM dithiothreitol. 36  
The sizes of vesicles incubated in PBS with or without 10 µM glutathione were almost the 
same even 48 h after the start of the experiment, implying that the extracellular reducing 
environment has little effect on the integrity of the vesicles. However, the intracellular or 
cytosolic reducing environment (corresponding to 10 mM glutathione) has a massive impact on 
the disassembly of the vesicles, raising the possibility of future use of these dendrimer-based 
vesicles as redox-responsive drug delivery systems for cancer treatment, as cancer cells have 
even further elevated intracellular glutathione concentration.  
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Figure 6. Evaluation of gluthatione sensitivity of the dendrimer-based vesicles: 
- Hydrodynamic size distribution of low-cholesterol (A) and high-cholesterol (B) dendrimer-
based vesicles (100 µg/mL in PBS, pH 7.4) at different time intervals, in presence or in absence 
of glutathione (GSH) (10 µM and 10 mM) at 37 oC (n=3) 
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- Fluorescence emission spectra of Nile Red in PBS (pH 7.4) (C), alone or in presence of low-
cholesterol (DPSCL) and high-cholesterol (DPSCH) dendrimer-based vesicles (100 µg/mL in 
PBS, pH 7.4) 
- Release profile of Nile Red (D) from low-cholesterol (DPSCL) and high-cholesterol (DPSCH) 
dendrimer-based vesicles (100 µg/mL in PBS, pH 7.4), in absence or presence of GSH (10 µM 
and 10 mM) at different time intervals.  
 
Redox-sensitive release of Nile Red from the vesicles 
The successful entrapment of Nile Red in the bilayer of the vesicles (with drug loading 
efficiencies of respectively 0.14 % and 0.17 % for low- and high-cholesterol dendrimer-based 
vesicles) was shown by an increase in fluorescence intensity of Nile Red in presence of the 
vesicles (543, 703 and 10 fluorescence arbitrary units respectively with low-cholesterol vesicles, 
high-cholesterol vesicles and free Nile Red solution), with a concomitant blue shift of 24 nm for 
λmax of the entrapped dye (λmax: 632 nm) compared to the free solution (λmax: 656 nm) (Figure 
6C). The increased fluorescence intensity observed in the presence of high-cholesterol vesicles 
might be attributed to the higher cholesterol content of these vesicles, thus facilitating the 
entrapment of the lipophilic dye in the lipid bilayer of the vesicles. 
In presence of glutathione, a tripeptide having a free thiol, the vesicle bilayers are expected to 
be disassembled due to thiol-disulphide reaction, with a concomitant release of the encapsulated 
Nile Red.45 This naturally occurring biological thiol is present at different concentrations in 
extracellular (10 µM) and intracellular (10 mM) compartments. The fluorescence intensity of the 
entrapped Nile Red was monitored in function of time in presence or absence of glutathione (10 
µM and 10 mM).  The fluorescence intensity of Nile Red entrapped in low-cholesterol- and high-
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cholesterol-vesicles sharply decreased in presence of 10mM glutathione (Figure S8). This effect 
was most pronounced at 48 h after the start of the incubation with the low-cholesterol vesicles 
(299 and 486 arbitrary units for Nile Red respectively entrapped in low-and high-cholesterol 
vesicles). The decrease of fluorescence intensity was also observed in the presence of 10 µM 
glutathione, but to a lesser extent (453 and 620 arbitrary units for Nile Red respectively 
entrapped in low-and high-cholesterol vesicles at 48 h). 
The cumulative release profile of Nile Red from the vesicles in presence or absence of 
glutathione indicated that both vesicles are more fragile in intracellular redox conditions rather 
than in extracellular conditions, leading to a higher and faster release of Nile Red in more 
reductive conditions (up to 40% and ~ 25% Nile red release from respectively the low-
cholesterol and high-cholesterol dendrimersomes in presence of 10 mM glutathione) (Figure 
6D). Although both low- and high-cholesterol vesicles showed a sustained release of the dye, the 
high-cholesterol vesicles having more disulphide-conjugated lipophilic units were more resistant 
to higher glutathione concentration, resulting in a lower release of the guest compared to its low-
cholesterol counterpart. The sustained release of the hydrophobic Nile Red dye may be due to the 
limited access of the hydrophilic glutathione to the highly hydrophobic and compact bilayer 
region of the vesicles and would be advantageous for the slow release of a drug in conjunction 
with an associated therapeutic entity with a faster release, such as therapeutic nucleic acid. These 
results were close to that observed with redox-sensitive PEGylated amphiphilic methacrylate-
based polymeric nanoassemblies without any cholesterol (up to 40% Nile Red release when in 
presence of 10 mM glutathione). 45  
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Characterization of dendriplex formation 
 Evaluation of DNA condensation  
The cholesterol-bearing PEGylated dendrimers can efficiently bind to negatively charged 
DNA through electrostatic interactions between the protonated primary amines of the dendrimers 
and the negatively charged phosphodiester groups of the DNA to form dendrimer: DNA 
complexes (dendriplexes). The fluorescence of PicoGreen® significantly increases on 
intercalation with double stranded DNA. The electrostatic interactions between the negatively 
charged DNA and positively charged dendrimers on formation of the dendriplex condense the 
DNA and reduce the number of PicoGreen® binding sites, resulting in a decrease in the 
fluorescence intensity of the PicoGreen® solution. 
Both low-cholesterol and high-cholesterol dendrimers were able to condense more than 85% 
of the DNA at all tested ratios for the low-cholesterol dendrimer, and at dendrimer: DNA weight 
ratios of 1:1 and higher for the high-cholesterol dendrimer, which displayed less primary amines 
at its periphery than its low-cholesterol counterpart (Figures 7A and B). DNA condensation 
occurred instantly and was found to be stable for at least 24 h. DNA condensing ability of these 
modified dendrimers was of the same range to that reported for generations 1, 2 and 3-PAMAM 
dendrimers conjugated to 40% cholesterol, 30-31 PEGylated poly(amidoamine) dendron-bearing 
lipids-based lipoplexes, 16 octadecyl alkyl chain-bearing generations 2- and 3- PAMAM 
dendrons forming lipoplexes following probe sonication 46 (up to 100% for all of these 
formulations).  
A gel retardation assay confirmed the complete and partial DNA condensation by cholesterol-
bearing dendrimers (Figures S9 and S10). At dendrimer: DNA weight ratios higher than 1:1, 
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DNA was fully condensed by cholesterol-bearing DAB, thus preventing ethidium bromide to 
intercalate with DNA. No free DNA was therefore visible at these ratios.  
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Figure 7. Evaluation of the DNA complexation of the low-cholesterol and high-cholesterol 
dendrimers: 
- DNA condensation of low-cholesterol (A) and high-cholesterol (B) dendriplexes using 
PicoGreen® reagent at various durations and dendrimer: DNA weight ratios: 20:1 (■, black), 
10:1 (●, red), 5:1 (▲, blue), 2:1 (▼, magenta), 1:1 (♦, green) and 0.5:1 (◄, violet). Results are 
expressed as mean ± SEM (n=4) 
- Size (C) and zeta potential (D) of low-cholesterol (○) and high-cholesterol (■) dendriplexes at 
various dendrimer: DNA weight ratios, in 5% glucose at 37 oC (n=3) 
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Size and zeta potential measurement 
Low-cholesterol dendriplex displayed an average size lower than 150 nm at all dendrimer: 
DNA weight ratios used, with a low polydispersity index (0.15 to 0.3). By contrast, the size of 
high-cholesterol dendriplex initially decreased with increasing dendrimer: DNA weight ratios 
ranging from 0.5:1 to 5:1 (from 127.6 ± 3.7 nm to 95.8 ± 4.2 nm) due to the increase in 
hydrophobicity, as previously described in the case of cholesterol modified spermine-
functionalised dendrons. 47 It then increased to reach a maximum of 320.8 ± 70.2 nm at a ratio of 
20:1 which might be due to losing its hydrophobic balance (Figure 7C). 
Overall, dendriplexes showed a smaller hydrodynamic diameter due to the presence of the 
highly hydrophobic cholesterol in the backbone, leading to the formation of more compact 
dendriplexes in comparison to not only C18 alkyl chain-modified generation 3- PAMAM 
dendrimers, but also cholesterol-modified generations 1, 2 and 3- PAMAM-based 
dendriplexes.16,30-31 Both low-cholesterol and high-cholesterol dendriplexes presented an overall 
average size lower than the unmodified DAB dendriplex, which had an average size of 196 nm 
(polydispersity index: 0.683). 8 This smaller size will further facilitate their extravasation to 
cancer cells.  
Zeta potential experiments demonstrated that the dendriplexes were bearing slightly increasing 
positive surface charge comprised between 21.4 ± 0.9 and 41.1 ± 0.6 mV for most ratios, but a 
negative charge of around ‒20 mV at a dendrimer: DNA weight ratio of 0.5:1. There was no 
significant differences of results between low- and high-cholesterol dendriplexes (Figure 7D). 
These dendriplexes showed a much higher positive zeta potential in comparison with PEGylated 
poly(amidoamine) dendron-bearing lipids-based lipoplexes (~4-10 mV) 25 and with generations 
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1, 2 and 3-PAMAM dendrimers conjugated to 40% cholesterol (~18-23 mV).30-31 This increased 
zeta potential would therefore further facilitate the uptake of these dendriplexes by cancer cells.  
 
Observation of the morphology of the dendriplexes 
Transmission electron microscopic images showed the presence of dendrimer-based vesicles 
even after complexation with DNA, at dendrimer: DNA weight ratios 5:1 and 10:1 (Figure 8). 
Both the dendrimers have retained their ability to form vesicles with sizes lower than 100 nm in 
presence of DNA, unlike other C17 alkyl chain-modified polyamine-based dendrimersomes that 
transformed from vesicular forms to micellar structures in presence of siRNA.34 Low-cholesterol 
vesicles appeared to form smaller vesicles at a ratio 5:1 than at a ratio 10:1, unlike the high-
cholesterol vesicles that seemed to be of similar size at both ratios.  
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Figure 8. Unstained TEM images of low-cholesterol (A and B) and high-cholesterol (C and D) 
dendriplexes at dendrimer: DNA weight ratios of 5:1 (A and C) and 10:1 (B and D) 
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In vitro analysis 
Evaluation of cell viability 
The viability of PC-3 cells following treatment with low-cholesterol vesicles was maintained 
up to a dendrimer concentration of 40 µg/mL for 24 h incubation (58.7 ± 12.6 % viability) and 
25 µg/mL for 48 h and 72 h incubation (64.5 ± 11.1 and 56.7 ±17.6 % viability respectively) 
(Figure 9A).  
Replacing low-cholesterol dendrimersomes with high-cholesterol dendrimersomes led to a 
decrease in cell viability, which remains constant up to a dendrimer concentration of 35 µg/mL 
for 24 h and 48 h incubation (71.9 ± 10.4 and 66.4 ± 11.4 % viability respectively) and 40 µg/mL 
for 72 h incubation (66.4 ± 8.9 % viability) (Figure 9B). Similar cell viability was observed 
following treatment of HeLa-Luc cells and Huh-7-Luc cancer cell lines with cationic PAMAM 
dendron-bearing lipids (more than 70% viability up to 32 µg/mL after 48 h). 48 Low- and high-
cholesterol dendrimersomes led to an improved cell viability compared with cholesterol-
modified generations 3- and 5- PAMAM dendrimers 49, which might be due to the presence of 
PEG and comparatively lower amount of cholesterol in the backbone.  
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Figure 9. Cell viability of the low-cholesterol (A) and high-cholesterol (B) dendrimers on PC3 
prostate cancer cells at various concentrations and treatment durations (n=6) (* : P <0.05 
compared with dendrimer concentration at t= 0 h)  
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Evaluation of gene expression of the dendrimers complexed with DNA 
Both low-and high-cholesterol dendrimers complexed to DNA led to gene transfection at all the 
durations tested on PC3 cell line with different amounts (Figure 10). The highest transfection 
level following treatment with low-cholesterol dendrimer complex was obtained at dendrimer: 
DNA weight ratio of 5:1 after 72 h treatment. At this ratio, gene expression was 4.92-fold higher 
than following treatment with DNA (1.30 ± 0.07 U/mL), but 1.33-fold lower than with DAB 
dendriplex (8.55 ± 0.64 U/mL). 
When replacing low-cholesterol dendrimer by high-cholesterol dendrimer, the highest gene 
expression resulted from treatment with the dendrimer complex at a ratio of 10:1, after 72 h 
treatment. It was 4.98-fold higher than following treatment with DNA (1.2 ± 0.15 U/mL), 1.26- 
fold lower than with DAB dendriplex (7.59 ± 1.38 U/mL), and similar to the highest gene 
expression obtained with its low-cholesterol counterpart. Treatment with naked DNA only 
resulted in weak levels of gene expression, as expected. Both cholesterol-modified DAB-
dendriplexes showed slightly less transfection efficacy compared with unmodified DAB 
dendriplex after 3 days of treatment. This might be due to a decrease in proton sponge effect, 
occurring as a consequence of the substitution on the dendrimers. As cholesterol has previously 
been shown to disrupt endosomal membrane 47, another possibility would be that the dendrimers 
should be conjugated to an even higher amount of cholesterol to increase their gene expression 
ability. This hypothesis is further reinforced by the fact that all the generation 1-, generation 2- 
and generation 3-PAMAM dendrimers conjugated to cholesterol at 40% mole ratio of 
cholesterol/primary amine displayed a significantly higher gene expression than their unmodified 
dendriplexes.30-31  
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Figure 10. Transfection efficacy of low-cholesterol (A) and high-cholesterol (B) dendriplexes at 
various dendrimer: DNA weight ratios in PC3 prostate cancer cells. (Optimal DAB: DNA ratio: 
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5:1) (n=5) (A: P <0.05 for all treatments compared with DAB, B: only 10:1 treatment was not 
significantly different from DAB treatment) 
 
Cellular uptake of dendriplexes 
Qualitative analysis 
The cellular uptake of the complex formed between fluorescein-labeled DNA and dendrimer-
based vesicles, was qualitatively confirmed in PC-3 cells using confocal microscopy (Figure 11). 
Fluorescein-labeled DNA was disseminated in the cytoplasm of the cells after treatment with 
both low-and high-cholesterol vesicles, at both 5:1 and 10:1 ratios.  The DNA uptake appeared to 
be the highest following treatment with high-cholesterol vesicles at a dendrimer: DNA weight 
ratio of 10:1. It also appeared to be more pronounced in the cells treated with the vesicle 
complexes than with DAB dendriplex. No co-localization of DNA in the nuclei was visible after 
2 h incubation.  
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Figure 11. Confocal microscopy images of the cellular uptake of fluorescein-labelled DNA (2.5 
μg/dish), complexed with low-cholesterol dendrimer (A: dendrimer: DNA ratio 5:1, B: 
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dendrimer: DNA ratio 10:1), high-cholesterol dendrimer (C: dendrimer: DNA ratio 5:1, D: 
dendrimer: DNA ratio 10:1), DAB dendrimer (E) or free in solution (F), after 2h incubation with 
PC3-Luc cells. Blue: nuclei stained with DAPI (excitation: 405 nm laser line, bandwidth: 415–
491 nm), green: fluorescein-labelled DNA (excitation: 453 nm laser line, bandwidth: 550–620 
nm) (Magnification: ×40). 
 
Quantitative analysis 
Qualitative results were quantitatively confirmed by flow cytometry. Treatment of PC3 cells 
with the low-cholesterol complex resulted in the highest cellular fluorescence at a dendrimer: 
DNA ratio of 5:1 (3970 ± 184 arbitrary units (a.u.)), which was respectively 12.5-fold and 15.4- 
fold higher than that observed after treatment with DAB dendriplex (315 ± 10.50) and DNA 
solution (257 ± 6 a.u.) (Figures 12 and S11). It was also 1.3-fold higher than that when using a 
dendrimer: DNA weight ratio of 10:1 instead of 5:1 (3022 ± 55 a.u.).  
Increased cellular fluorescence was also observed following treatment with high-cholesterol 
complex at a 10:1 ratio (2775 ± 81 a.u.). It was respectively 8.8-fold and 10.78-fold higher than 
that observed following treatment with DAB dendriplex and DNA solution, but also 1.9-fold 
higher than when using a ratio of 5:1 (1414 ± 63 a.u.).  In addition, treatment of the cells with 
naked DNA resulted in a weak DNA uptake, demonstrating the failure of DNA to be taken up by 
prostate cancer cells without the assistance of a carrier. 
This enhanced delivery of DNA to the cancer cells most likely resulted from the highly 
positive charges of the dendriplexes, as positive charges increase their electrostatic interactions 
with the negatively charged cellular membranes and facilitate cellular uptake. 37 However, this 
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did not result in an increased expression of the reporter gene compared with the unmodified 
DAB dendriplex.  
 
 
Figure 12. Quantification of the cellular uptake of fluorescein-labeled DNA (2.5 μg/well), 
complexed with low- or high-cholesterol dendrimers (DPSCL and DPSCH respectively), DAB 
dendrimer, or free in solution, after 2 h incubation with PC3-Luc cells, using flow cytometry 
(n=3) (*: P <0.05 compared with DAB-DNA) 
 
To the best of our knowledge, this is the first report on cholesterol-bearing PEGylated 
polypropylenimine dendrimers forming spontaneous, redox-sensitive, cationic stable vesicles 
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able to carry hydrophilic or hydrophobic compounds as well as DNA, leading to gene expression 
in prostate cancer cells. Other cholesterol-modified dendrimers have previously been reported 
(spermine-functionalized dendrons conjugated with cholesterol 47, cholesterol-conjugated 
PAMAM dendrimers) 30-31, 49, but for use as a non-viral gene delivery system only, and without 
redox sensitivity. Amphiphilic dendrimers based on polypropylenimine dendrimers have also 
been shown to self-assembly, but without redox-sensitivity or entrapment of any drugs or genes. 
50 Redox-responsive PAMAM has previously been reported as delivery systems, but to deliver 
either DNA or hydrophobic drug, and this without the formation of vesicles. 51-52 These novel 
cholesterol-bearing PEGylated poly(propylene imine) dendrimer-based vesicles therefore hold 
promising prospects as redox-sensitive drug and gene delivery systems for cancer therapy.  
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CONCLUSION 
In this proof of concept study, two disulphide-linked cholesterol-bearing PEGylated dendrimers 
have been successfully synthesized through in situ two-step reaction. Both the low and high 
cholesterol-bearing dendrimers were able to spontaneously self-assemble into stable vesicles in 
PBS (pH 7.4), with lower critical aggregation concentration values for high cholesterol-bearing 
vesicles. These cationic, nano-sized vesicles, or dendrimersomes, were able to entrap both 
hydrophilic and hydrophobic guests, and also showed a redox-responsive sustained release of the 
entrapped guests at higher glutathione concentration corresponding to reducing environment in 
the intracellular compartment. In addition, both dendrimeric vesicles were able to condense more 
than 85 % of the DNA at all tested ratios for the low-cholesterol vesicles, and at dendrimer: 
DNA weight ratios of 1:1 and higher for the high-cholesterol vesicles.  These vesicles resulted in 
an enhanced cellular uptake of DNA, by up to 15-fold compared with naked DNA with the low-
cholesterol vesicles. Consequently, they increased gene transfection on PC3 prostate cancer cell 
line, with the highest transfection being obtained with low-cholesterol vesicle complex at a 
dendrimer: DNA weight ratio of 5:1 and high-cholesterol vesicle complex at a dendrimer: DNA 
weight ratio of 10:1. These transfection levels were about 5-fold higher than that observed when 
treated with naked DNA. These novel cholesterol-bearing PEGylated dendrimer-based vesicles 
are therefore very promising as redox-sensitive drug and gene delivery systems for future 
applications in cancer therapy. 
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Figure S1. FTIR spectra of (A) low-cholesterol and (B) high-cholesterol dendrimers 
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Figure S2. FTIR spectra of (A) OPSS-PEG-SCM (B) DAB dendrimer and (C) thiocholesterol 
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Figure S3. 1H-NMR spectrum of low-cholesterol (A) and high-cholesterol (B) dendrimer (in 
CDCl3, 500 MHz ). 
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Figure S4. MALDI-TOF MS spectra of low-cholesterol (A) and high-cholesterol dendrimers (B) 
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Section S1. Lipid loading Calculations 
The amount of lipid or cholesterol (CHOL) loading to modified dendrimer is calculated as the 
weight of conjugated CHOLSH as a percentage of the total average molecular weight: 
Lipid-loading (%) = {(n x 401.72)/[M]+}x 100 
Where, n is the number of cholesterol conjugated to modified dendrimer and [M]+ is the average 
molecular weight of the modified dendrimers analyzed from MALDI-TOF MS.  
Low-cholesterol dendrimer (DPSCL), lipid loading (%) = {(1 x 401.72)/4210} x 100 = 9.54% 
High-cholesterol dendrimer (DPSCH), lipid loading (%) = {(2 x 401.72)/6492} x 100 = 12.37% 
 
 
 
Figure S5. 1H-NMR spectrum of high-cholesterol dendrimer (in D2O, 500 MHz) 
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Figure S6. Fluorescence spectra of N-Phenyl-1-naphthylamine in presence or absence of low-
cholesterol (A) and high-cholesterol (B) dendrimer dispersions at various concentrations in PBS 
buffer (pH 7.4)   
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Figure S7. Transmittance of low-cholesterol (■) and high-cholesterol (○) dendrimer-based 
vesicles in function of temperature (400 µg/mL, pH 7.4). 
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Table S1. Results of phase transition analysis for low-cholesterol (DPSCL) and high-cholesterol 
(DPSCH) vesicles by DSC 
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Figure S8. Fluorescence emission spectra of Nile Red entrapped in low-cholesterol (A, C, E) 
and high-cholesterol (B, D, F) dendrimer-based vesicles (100 µg/mL in PBS, pH 7.4) in presence 
of glutathione (10 µM (A, B) and 10 mM (C, D)) at various time intervals (control: no 
glutathione) (E, F) 
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Figure S9.  Gel retardation assay of low-cholesterol DAB (DPSCL) dendriplexes at various 
dendrimer: DNA weight ratios (0.5:1, 1:1, 2:1, 5:1, 10:1,20:1)  
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Figure S10. Gel retardation assay of high-cholesterol DAB (DPSCH) dendriplexes at various 
dendrimer: DNA weight ratios (0.5:1, 1:1, 2:1, 5:1, 10:1, 20:1) 
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Figure S11. Flow cytometry histograms of PC3-Luc cells following 2 hours incubation with 
low-cholesterol dendriplex (dendrimer: DNA weight ratio 5:1 (A) or 10:1 (B)), high-cholesterol 
dendriplex (dendrimer: DNA weight ratio 5:1 (C) or 10:1 (D)) (Controls: DAB dendriplex (5:1) 
(E), DNA solution (F)) 
